Real-World Data on the Prevalence of Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer in the Middle East and North Africa
PURPOSEAnaplastic lymphoma kinase (ALK) gene alterations are potent oncogenic drivers in non–small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting the ALK pathway are effective in treating ALK-positive NSCLC. Around 5% of Asian and White patients with NSCLC have ALK-positive tumors, b...
Main Authors: | Abdul Rahman Jazieh, Rabab Gaafar, Hassan Errihani, Hassan Jaafar, Fouad Al Dayel, Abeer A. Bahnassy, Hatem El Kadi, Mohamed Magdy Abdallah, Ghazi Zaatari |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2021-12-01
|
Series: | JCO Global Oncology |
Online Access: | https://ascopubs.org/doi/10.1200/GO.21.00067 |
Similar Items
-
Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase
by: Farina F, et al.
Published: (2014-08-01) -
Leukemic phase of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma
by: Vijaya S Gadage, et al.
Published: (2011-01-01) -
Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study
by: Hind El yacoubi, et al.
Published: (2020-05-01) -
Anaplastic Lymphoma Kinase in Cutaneous Malignancies
by: Severine Cao, et al.
Published: (2017-09-01) -
An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
by: Suzanne D. Turner
Published: (2017-10-01)